Capstan Therapeutics
Biotechnology company pioneering in vivo cell programming using lipid nanoparticle (LNP) technology to reprogram cells directly within the body, eliminating the need for ex vivo cell manufacturing.
Notes
Capstan Therapeutics is a biotechnology company developing in vivo cell programming therapies. The company uses lipid nanoparticle (LNP) technology to deliver genetic instructions directly to cells within the body, enabling the programming of immune cells in vivo without the need for traditional ex vivo cell manufacturing.
This approach aims to overcome key limitations of current cell therapies, including the complexity and cost of manufacturing, and could potentially make cell therapies more accessible to patients. The company is backed by Alexandria Venture Investments and other life sciences investors.
Team
- Gail Walkinshaw, Ph.D. - Chief Executive Officer
- LinkedIn: linkedin.com/in/gailwalkinshaw
- Richard Mulligan, Ph.D. - Co-founder (former Harvard professor, gene therapy pioneer)
- Kris Wood, Ph.D. - Chief Scientific Officer
Additional Research Findings
- Investor: Alexandria Venture Investments
- Focus on in vivo cell engineering/programming
- LNP (lipid nanoparticle) delivery technology
- Combines elements of cell therapy and gene therapy
- Aims to eliminate need for ex vivo cell manufacturing
- Headquarters in San Diego, California
- Developing platform for multiple therapeutic applications
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Alexandria Venture Investments | Pasadena, USA | cvc | seedseries-a+3 | 6 |